Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer: A Systematic Review and Meta-analysis

@article{Havrilesky2013OralCP,
  title={Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer: A Systematic Review and Meta-analysis},
  author={L. Havrilesky and P. Moorman and W. Lowery and J. Gierisch and R. Coeytaux and R. Urrutia and M. Dinan and Amanda J. McBroom and V. Hasselblad and G. Sanders and E. Myers},
  journal={Obstetrics \& Gynecology},
  year={2013},
  volume={122},
  pages={139–147}
}
OBJECTIVE: To estimate the overall reduction in ovarian cancer risk associated with the use of oral contraceptive pills (OCPs) and whether reduction in risk is affected by specifics of OCP use, such as formulation or duration of use. DATA SOURCES: We searched PubMed, Embase, the Cochrane Database of Systematic Reviews, and ClinicalTrials.gov for studies published from January 1990 to June 2012, with primary analysis of studies published since January 2000. METHODS OF STUDY SELECTION: We… Expand
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.
TLDR
The authors agree with the authors that oral contraceptive pill use can decrease the risk of developing ovarian cancer, but they believe that further studies still are required. Expand
Intrauterine Device Use and Ovarian Cancer Risk: A Systematic Review and Meta-analysis.
TLDR
Intrauterine device use is associated with a reduced incidence of ovarian cancer based on a review of existing retrospective data, and prospective investigation into the role of IUDs in ovarian cancer prevention is limited. Expand
Screening and Prevention of Ovarian Cancer
TLDR
Clinicians are recommended to encourage high-risk women who delay or decline risk- reducing surgery to discuss risk-reducing pharmacologic options in order to prevent ovarian cancer progression without elevation of breast cancer risk. Expand
What are the mechanisms of action of the different contraceptive methods to reduce the risk of ovarian cancer?
TLDR
Combined hormonal contraceptive use is an effective method of chemoprevention for OvCa in the general population and in women with genetic disorders and salpingectomy, better than tubal ligation, should be offered for ovarian/tubal/peritoneal cancer prevention. Expand
The Chemoprevention of Ovarian Cancer: the Need and the Options
TLDR
The role of risk assessment in the design of chemoprevention strategies for OvCa is discussed, candidate agents are described, and future directions in this field are assessed. Expand
Cancer incidence attributable to the use of oral contraceptives and hormone therapy in Alberta in 2012.
TLDR
Based on estimates, oral contraceptive use resulted in a net protective effect among the cancer sites studied, thus reducing the cancer burden in Alberta in 2012. Expand
Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.
TLDR
In women with a genetic predisposition to ovarian cancer, salpingo-oophorectomy reduces the risk of ovarian malignancy, and to a lesser degree of breast cancer, and in premenopausal women, bilateral salpingectomy should be preferred to tubal ligation. Expand
Endocrine interventions in women with BRCA1/2 mutations
TLDR
Oral contraceptives seem to slightly increase the breast cancer risk of BRCA1/2 mutation carriers, but they also have a tremendous protective effect against ovarian cancer. Expand
Breastfeeding factors and risk of epithelial ovarian cancer.
TLDR
Although this association decreases over time, it persists for more than 30 years, and longer cumulative duration, increasing number of breastfeeding episodes, and earlier age at first breastfeeding episode are each associated with increased benefit. Expand
Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017.
TLDR
Increasing IUD use outpaced declining OC use in premenopausal US women and there may be a resulting decreased gynecologic cancer risk as more women gain access to potentially risk-reducing contraceptives. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Oral contraceptive use for the primary prevention of ovarian cancer.
TLDR
There is insufficient evidence to recommend for or against the use of OCs solely for the primary prevention of ovarian cancer, and the harm/benefit ratio was much more favorable when protection against endometrial and colorectal cancers was added. Expand
Long‐term effects of oral contraceptives on ovarian cancer risk
TLDR
The present analysis indicates that, after taking into account duration of OC use, the OC protection from ovarian cancer persists for a long time after stopping use. Expand
Pooled analysis of 3 european case‐control studies of epithelial ovarian cancer: III. Oral contraceptive use
TLDR
The relationship between use of oral contraceptives and other contraceptive methods and the risk of ovarian cancer was examined in a combined analysis of 3 hospital‐based case‐control studies in Italy, the United Kingdom, and Greece, suggesting that the protection persists for 15 years or more after cessation of use and may be larger for use at younger age. Expand
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.
TLDR
It is suggested that oral contraceptives have already prevented some 200,000 ovarian cancers and 100,000 deaths from the disease, and that over the next few decades the number of cancers prevented will rise to at least 30,000 per year. Expand
Ovarian cancer and hormone replacement therapy in the Million Women Study
TLDR
Women who use HRT are at an increased risk of both incident and fatal ovarian cancer, and in women with epithelial tumours the relative risk for current versus never use of HRT was greater for serous than for mucinous, endometroid, or clear cell tumours. Expand
Prospective study of oral contraceptives and hypertension among women in the United States.
TLDR
Current users of oral contraceptives had a significant, moderately increased risk of hypertension, but among this group, only 41.5 cases per 10 000 person-years could be attributed to oral contraceptive use. Expand
Screening for ovarian cancer: a pilot randomised controlled trial
TLDR
The results show that a multimodal approach to ovarian cancer screening in a randomised trial is feasible and justify a largerrandomised trial to see whether screening affects mortality. Expand
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
TLDR
Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality. Expand
Screening for Ovarian Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement
  • V. Moyer
  • Medicine
  • Annals of Internal Medicine
  • 2012
TLDR
This recommendation applies to asymptomatic women and does not apply to women with known genetic mutations that increase their risk for ovarian cancer (for example, BRCA mutations). Expand
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
TLDR
TVS screening does not appear to be effective in detecting ovarian cancer in which ovarian volume is normal, and when performed annually, is associated with a decreases in stage at detection and a decrease in case-specific ovarian cancer mortality. Expand
...
1
2
3
...